3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Triple Negative Breast Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumors
1
Interventions
Injections
25
Carboplatin
17
Docetaxel
14
pembrolizumab
12
Paclitaxel
11
Bevacizumab
9
durvalumab
8
Cisplatin
8
Nivolumab
6
Fluorouracil
6
trifluridine tipiracil drug combination
5
tislelizumab
5
linifanib
5
Pemetrexed
5
Oxaliplatin
5
Leucovorin
5
zimberelimab
4
toripalimab
4
talazoparib
4
olaparib
4
Itraconazole
4
Irinotecan
4
Gemcitabine
4
Capecitabine
4
tremelimumab
3
sotorasib
3
sintilimab
3
fludarabine
3
depatuxizumab
3
atezolizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Solid Tumors
×
Maximum Tolerated Dose
×
Clear all
NCT02994953
2024-09-20
COMBO
EMD Serono
Phase 1
Terminated
52 enrolled
34 charts